脂肪酸侧链 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Halliwell B; Gutteridge JM (1984). "Oxygen toxicity, oxygen radicals, transition metals and disease". Biochemical Journal. 219 (1): 1–14. doi:10.1042/bj2190001. PMC 1153442. PMID 6326753. Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJ, Davies MJ, Dick TP, Finkel T, Forman HJ, Gems D, Janssen-Heininger Y, Kagan VE, Kalyanaraman B, Larsson NG, Mile GL, Nyström T, Poulsen HE, Radi R, Remmen HV, Schumacker PT, Thornalley PJ, Toyokuni S, Winterbourn CC, Yin H, Halliwell B. (2022) Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nature Metabolism 4, 651–662. Research articles
== Bibliography == Wolfram Saenger, Principles of Nucleic Acid Structure, 1984, Springer-Verlag New York Inc. Bruce Alberts, Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, and Peter Walter Molecular Biology of the Cell, 2007, ISBN 978-0-8153-4105-5. Fourth edition is available online through the NCBI Bookshelf: link Jeremy M Berg, John L Tymoczko, and Lubert Stryer, Biochemistry 5th edition, 2002, W H Freeman. Available online through the NCBI Bookshelf: link Astrid Sigel; Helmut Sigel; Roland K. O. Sigel, eds. (2012). Interplay between Metal Ions and Nucleic Acids. Metal Ions in Life Sciences. Vol. 10. Springer. doi:10.1007/978-94-007-2172-2. ISBN 978-94-007-2171-5. S2CID 92951134.
This led Santa Fe Opera to add one more performance. As well, Santa Fe Opera secured an agreement with the Dutch recording label Pentatone to produce a commercial recording of the opera, captured live from the Santa Fe Opera production. The director of the premiere production at Santa Fe Opera was Leonard Foglia, with set design by Robert Brill, lighting design by Brian Nason, costumes by David C. Woolard and projection design by Elaine J. McCarthy. Miguel Harth-Bedoya was the conductor. With respect to Opera Philadelphia, Cold Mountain is part of the company's "American Repertoire Program", a ten-year commitment to produce a contemporary American work each season. For the second production of Cold Mountain, at Opera Philadelphia, Higdon and Scheer made modest revisions. In late January 2016, Nathan Gunn withdrew from the Opera Philadelphia production because of a family medical emergency. Jarrett Ott, the understudy for Inman in both the Santa Fe Opera and Opera Philadelphia rosters, stepped into the role of Inman for the Opera Philadelphia performances. The Pentatone commercial recording of Cold Mountain was released in April 2016. It received two Grammy nominations.[1] In May 2016, Cold Mountain was the winner in the category of World Premiere at the International Opera Awards in London. In July 2019, Cold Mountain made its West Coast Premiere at the Music Academy of the West 2019 Summer Festival.
In food science, water activity (aw) of a food is the ratio of its vapor pressure to the vapor pressure of water at the same temperature, both taken at equilibrium. Pure water has a water activity of one. Put another way, aw is the equilibrium relative humidity (ERH) expressed as a fraction instead of as a percentage. As temperature increases, aw typically increases, except in some products with crystalline salt or sugar. Water migrates from areas of high aw to areas of low aw. For example, if honey (aw ≈ 0.6) is exposed to humid air (aw ≈ 0.7), the honey absorbs water from the air. If salami (aw ≈ 0.87) is exposed to dry air (aw ≈ 0.5), the salami dries out, which could preserve it or spoil it. Lower aw substances tend to support fewer microorganisms since these get desiccated by the water migration. Water activity is not simply a function of water concentration in food. The water in food has a tendency to evaporate, but the water vapor in the surrounding air has a tendency to condense into the food. When the two tendencies are in balance— and the air and food are stable—the air's relative humidity (expressed as a fraction instead of as a percentage) is taken to be the water activity, aw. Thus, water activity is the thermodynamic activity of water as solvent and the relative humidity of the surrounding air at equilibrium.
Sources: en.wikipedia.org
From the analysis of individual atoms within proteins to the genetic and protein-based reconstruction of complex biological systems, the department provides various vital links between basic and translational biomedical research, contributing heavily to the C700 Biochemistry and C130 Biomedical Sciences undergraduate degree programmes and MSc taught courses in Bioinformatics and Biotechnology.
chemical processing, electricity, batteries and electronic components, construction and architecture, healthcare and pharmaceutics, biomedical research, ultra-pure applications, nuclear waste handling, petrochemical, oil and gas, food, beverage processing, water, wastewater management.
==== Member of the Order of the British Empire (MBE) ==== Military Commander Steven Andrews, Royal Navy, D257452S. Lieutenant Commander Ross Donald Balfour, Royal Navy, C040712E. Warrant Officer 1 James Adrian Cuthbert, Royal Marines, P047210N. Warrant Officer 1 Engineering Technician (Communication and Information Systems) Steven Gilbertson, Royal Navy, D242982T. Commander Martin John Howard, Royal Navy, C041681L. Lieutenant Commander Alexander Rowan Marsh, Royal Navy, 30033538. Commander Paul O'Dooley, Royal Naval Reserve, C900344D. Chief Petty Officer Engineering Technician (Marine Engineering) Michael John Stephens, Royal Navy, D258366B. Leading Seaman (Diver) Rory Edward Cartwright-Taylor, Royal Navy, 30050838. Lieutenant Sam David Thompson, Royal Navy, 30023663. Commander Roger Simon Wyness, Royal Navy, C037182G. Major John Edward BAILEFF, Royal Regiment of Artillery, 30121479. Major Allan Paul Beard, Intelligence Corps, 25132230. Sergeant Daniel Adam Powderham-Bissell, Intelligence Corps, 25179642. Lieutenant Colonel John George Bradbury, Corps of Royal Electrical and Mechanical Engineers, Army Reserve, 552247. Major (now Acting Lieutenant Colonel) Keith Michael Timothy Brooks, , Royal Regiment of Artillery, Army Reserve, 511819. Captain Barry Lee Byron, , General Service Corps, Army Reserve, 24751476. Captain Giles Alexander Leighton Clarke, The Royal Logistic Corps, 30082571. Major Lisa Jane Clarke, Adjutant General's Corps (Staff and Personnel Support Branch), W0815832. Major James Philip Dott, The Parachute Regiment, 30011021.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.